AstraZeneca & Bristol Myers Squibb
9 shared events · Importance 3 · Last updated Aug 11, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
AstraZeneca: AstraZeneca is the initiator of the merger talks, seeking to expand its US presence. Its shares fell over 7% on the news, reflecting investor skepticism about the deal's value and execution risk.
Bristol Myers Squibb: Bristol Myers Squibb is the target of the potential merger, which would provide it with a significant premium and access to AstraZeneca's pipeline. Its shares have risen 43% in the past year, and the deal could further boost its valuation.
Aug 02, 2026 · 60 articles
Business
AstraZeneca: AstraZeneca is the central company, facing another pipeline setback with the discontinuation of the volrustomig trial. Despite this, it reported positive results from other trials and reaffirmed its 2030 revenue target, with shares rising slightly.
Bristol Myers Squibb: Bristol Myers Squibb was mentioned in the context of brief merger speculation involving AstraZeneca, which triggered investor backlash but is not directly part of this event.
Aug 17, 2026 · 20 articles
Domestic
AstraZeneca: AstraZeneca, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Bristol Myers Squibb: Bristol Myers Squibb, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Business
AstraZeneca: Investors punished the stock over merger talks with Bristol Myers Squibb.
Bristol Myers Squibb: Reportedly in merger talks with AstraZeneca, which could create a $400 billion drugmaker.
Jul 14, 2026 · 280 articles
Business
AstraZeneca: AstraZeneca is mentioned as an existing AWS customer, but this event does not directly impact it.
Bristol Myers Squibb: Bristol Myers Squibb is mentioned as another pharmaceutical company partnering with AI firms, but this event does not directly impact it.
Aug 10, 2026 · 7 articles
Business
AstraZeneca: AstraZeneca is mentioned as a prior acquirer of KC Pharmaceuticals, illustrating sector M&A activity.
Bristol Myers Squibb: Bristol Myers Squibb is mentioned as a prior acquirer in the sector, highlighting the trend of radiopharmaceutical consolidation.
Aug 03, 2026 · 7 articles
Business
AstraZeneca: AstraZeneca recently acquired a stealth company based on discoveries made by Anna Greka>>>'s team.
Bristol Myers Squibb: Bristol Myers Squibb acquired the lead asset from Goldfinch Bio, a company founded by Anna Greka>>>.
Jun 03, 2026 · 6 articles
80
AstraZeneca explored merger Bristol Myers SquibbAI earnings drive record...
70
Bristol Myers Squibb held merger talks AstraZenecaAI earnings drive record...
ERGEN INTELLIGENCE
Explore this relationship live
Track how AstraZeneca and Bristol Myers Squibb interact across events, view sentiment trends, and discover connected entities.
Open Dashboard